Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics Inc., a clinical-stage pharmaceutical company specializing in kidney disease treatments, has announced the TSX Venture Exchange approval to reprice outstanding common share purchase warrants from its October 2021 US IPO. The new terms feature a reduced exercise price and a warrant acceleration provision that allows for a forced conversion if the stock trades above a certain threshold for ten consecutive days. The move aims to advance XORTX’s development of innovative therapies targeting purine metabolism and xanthine oxidase to combat uric acid production.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
